On-Demand
Welcome
We would like to invite you to our webinar “Management of lymphoma patients treated with B-cell depleting agents”. Four national speakers will highlight various aspects of B-cell depletion in lymphoma, specifically in DLBCL (diffuse large B-cell lymphoma), and the potential secondary immunodeficiencies that may result.
For questions or concerns, please contact:
Dr. Christoph Schneider
Head of Marketing & Sales CSL Behring
christoph.schneider@cslbehring.com
079 580 57 49
Dr. Simone Gruber
Medical Advisor Incyte
sebener@incyte.com
079 658 56 83
Note: The webinar is intended for healthcare professionals only.
Your opinion counts!
(1=min, 10=max)
Program
Time | Title | Presenter |
---|---|---|
17:00 –17:05 | Welcome | Chair |
17:05 –17:35 | 2nd-line treatment of patients with DLBCL not eligible for intensive options | PD Dr. Jeroen Goede, Kantonsspital Winterthur |
17:35–18:05 | Difficulties in handling R/R DLBCL patients with B-cell targeting agents: Challenging patient cases | Dr. Noémie Lang, HUG Genève |
18:05–18:10 | Discussion part I | |
18:10–18:40 | Immunological aspects during B-cell depletion | Dr. Urs Steiner, Inselspital Bern |
18:40–19:10 | Management of secondary immunodeficiencies in the hemato-oncological setting | Dr. Nathan Cantoni, Kantonsspital Aarau |
19:10–19:15 | Discussion part II |
Organized and sponsored by
Legal notice
CSL Behring and Incyte have engaged POMCANYS Marketing AG to conduct the webinar/webcast. For information on how your personal data is processed click on the following links for CSL Behring and Incyte.
Please note that by participating in the webcast it can be concluded that you are entering into a customer relationship with CSL Behring and/or Incyte Biosciences.
CSL Behring AG, Wankdorfstrasse 10, CH-3014 Bern / Incyte Biosciences International Sàrl, Rue Docteur-Yersin 12 CH-1110 Morges